Gojo, Javelle B.
HRN: 28-18-59 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/03/2025
CEFOTAXIME 500MG (VIAL)
12/03/2025
12/17/2025
IV
140mg
Q12
Neonatal Tetanus
Checking Final Appropriateness
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes